IanFVA BRAND OF IONAFAIan Financial VisionAI-Driven. Independent. For Everyone.

Healthcare Valuations

Latest fair-value assessments and target prices by sector.

$524.09

TMO Valuation Report 2026-07-25

Thermo Fisher Scientific (TMO) demonstrates a diversified revenue base across pharmaceuticals, biotech, academia, and industry, driving consistent performance despite macroeconomic headwinds. Recent Q2 2026 results exceeded expectations with 10% revenue growth and 13% EPS increase, prompting upward revised guidance. Strategic initiatives focus on high-growth areas like gene/cell therapy and bioproduction, bolstered by acquisitions like Clario and collaborations with ImmuPharma and Arcturus. While institutional activity shows some portfolio rebalancing, a consistent dividend and defensiveness support a premium valuation. Financial analysis reveals stable cash flow, efficient supply chain management, and a moderate level of debt. However, DCF analysis suggests the share price may be approaching fair value. R&D investment lags peers, and while the company shows operational resilience, margin expansion remains a challenge. Valuation models indicate a moderate dispersion, with a current trading price of $568.26 potentially overvalued compared to near-term targets ranging from $487 to $524, suggesting a potential correction or stabilization in the coming quarters. Overall, TMO presents as a mature, stable entity focused on long-term growth within scientific innovation, but requires monitoring of margin performance and R&D investment.

$232.77

MOH Valuation Report 2026-07-24

Molina Healthcare operates as a managed healthcare organization serving government-sponsored programs like Medicaid and Medicare, generating revenue through per-member premiums. Recent Q2 2026 results showed GAAP income of $1.19/share (adjusted $1.51), a decline from the prior year despite exceeding estimates, attributed to decreased revenue and membership offset by expense reductions. The company raised 2026 guidance anticipating improved future performance through cost discipline. An impending move from the S&P SmallCap 600 to the S&P MidCap 400 reflects increased market capitalization, though share price volatility was observed. Financial health is tied to working capital and cost management, with a focus on operational efficiency. Strategic shifts include a move away from Medicare Advantage Prescription Drug plans towards dual-eligible members, driven by regulatory changes and a focus on margin restoration. Management emphasizes organic growth, acquisitions, and technology investment. Macroeconomic factors like stable GDP and low unemployment support demand, but inflation poses a risk to medical costs. While recent performance shows challenges, the company’s strategic focus and anticipated index inclusion warrant further investigation to assess potential value. Valuation metrics suggest potential undervaluation, but volatility and evolving risks require careful consideration.

$707.96

MEDP Valuation Report 2026-07-24

Medpace Holdings is a contract research organization experiencing revenue growth, recently reaching a 52-week high following a 17.2% year-over-year revenue increase to $707.3 million and exceeding earnings estimates at $4.25 per share. Management revised upward its 2026 revenue guidance to $2.805-$2.885 billion, supported by a 1.13x net book-to-bill ratio and 24.1% backlog conversion rate. While demand for CRO services remains strong, Medpace faces a lengthening award-to-revenue cycle and monitors cancellations. Capital allocation focuses on organic growth, including lab capacity and technology, with AI benefits expected to be modest near-term. The company maintains a low working capital intensity but faces valuation considerations due to a premium relative to peers. Macroeconomic conditions are stable, supporting operations, though inflationary pressures and elevated interest rates are monitored. Strategic focus remains on full-service offerings and consistent financial performance, with a recent emphasis on cost management and operational efficiency. R&D investment is absent, potentially impacting long-term innovation. Valuation suggests a moderate dispersion with a target price of $640 in one year and $707.96 in two years, though a short-term correction to $541.12 is anticipated.

$212.48

DHR Valuation Report 2026-07-22

Danaher Corporation is a diversified industrial technology company with Life Sciences as its primary revenue driver, characterized by recurring revenue from consumables and services. Recent financial performance showed EPS exceeding estimates, but a revised lower revenue outlook—driven by bioprocessing delays—negatively impacted share price despite margin expansion via operational excellence (DBS). Investor activity is mixed, with some increasing positions while others reduce holdings, reflecting caution about growth sustainability. Valuation remains premium, necessitating reassessment given revised growth expectations. Macroeconomic stability is offset by inflationary pressures potentially impacting demand. While GDP growth supports Life Sciences investment, inflation could increase costs. Diagnostics and Environmental Solutions face budget constraints. Danaher’s strategy focuses on operational efficiency, strategic acquisitions (like Masimo), and a shift towards “second curve” growth through R&D. Over the past four quarters, Danaher has demonstrated adaptability, prioritizing operational efficiency, core sales growth, and strategic acquisitions. While leverage has increased due to acquisitions, strong cash flow provides financial flexibility. Risks include patent litigation, supply chain disruptions, and tax liabilities. The company’s ability to address bioprocessing challenges, maintain margins, and execute its capital allocation strategy will be critical for future performance.

$459.12

UNH Valuation Report 2026-07-19

UnitedHealth Group (UNH) is a vertically integrated healthcare solutions provider with revenue from diversified areas including insurance (UnitedHealthcare) and healthcare services/pharmacy (Optum). Profitability relies on scale, data analytics, and clinical outcomes. Recent Q2 earnings exceeded expectations due to improved medical cost ratios and Optum growth, leading to increased 2026 EPS guidance and a doubled share repurchase program. Despite this, commercial margins face pressure and macroeconomic factors, particularly AI spending volatility, create headwinds. UNH strategically emphasizes AI integration across operations, commercializing it as a service, and benefits from the recent FDA approval of an oral PCSK9 inhibitor impacting Optum Rx. While analysts upgraded the stock post-earnings, valuation concerns persist. Macroeconomic factors like stable unemployment, inflation, and interest rates influence performance, requiring cost management and adaptation. Over the past year, UNH has shifted towards aggressive growth via innovation, acquisitions, and operational efficiency. Risk profiles have evolved, with regulatory scrutiny and medical cost estimates as key concerns. The company demonstrates strengthening competitive positioning, driven by its integrated model and expanding TAM, but faces challenges in consistently delivering returns exceeding its cost of capital. Capital allocation balances growth with shareholder returns, while maintaining a substantial debt load.

$536.32

ISRG Valuation Report 2026-07-17

Intuitive Surgical dominates the medical device industry with its da Vinci robotic surgical systems, generating revenue through system sales, recurring instrument revenue, and related services. Recent financial performance shows top-line growth exceeding expectations, but investor concern centers on decelerating U.S. procedure volume growth and potential insurance coverage impacts. The company is mitigating these risks by developing tiered robotic platforms, integrating AI, and expanding its service ecosystem to demonstrate value. Strategically, Intuitive Surgical focuses on R&D reinvestment and acquisitions to broaden its product portfolio and geographic reach, maintaining efficient working capital. While macroeconomic factors like inflation and interest rates present challenges, a stable economic outlook supports healthcare spending. The company’s strategic shift towards leasing arrangements and expanding its service offerings aims to drive sustainable growth and enhance shareholder value. Recent risk factors include GLP-1 medication impacts on procedure volume, supply chain vulnerabilities, and increasing competition. Despite these headwinds, Intuitive Surgical’s commitment to innovation, operational efficiency, and a widening economic moat position it for continued leadership, contingent on stabilizing procedure growth and navigating evolving reimbursement landscapes. Management’s evolving capital allocation priorities and focus on long-term shareholder value creation further support a positive outlook.

$121.75

ABT Valuation Report 2026-07-17

Abbott Laboratories is a diversified healthcare company with revenue from pharmaceuticals, diagnostics, nutrition, and medical devices, prioritizing volume sales alongside higher-margin, technology-driven segments. Recent performance shows strengthening, driven by diagnostics and medical devices, despite nutritional segment weakness, boosted by the Exact Sciences acquisition. While earnings growth and substantial shareholder returns ($2.1B in Q2) demonstrate strong cash flow, the current valuation (18x earnings) is premium compared to peers, requiring sustained growth and a strong balance sheet (A+ S&P). Macroeconomic stability supports healthcare demand, but inflation poses cost pressures. Abbott is adapting through innovation in cardiovascular, diabetes, and diagnostics, and strategic acquisitions. R&D investment lags industry averages, and the company faces cyclical volatility in revenue and net margins, alongside risks from regulatory scrutiny, supply chain fragility, and tax litigation. Recent management shifts emphasize aggressive growth, but maintaining momentum requires efficient capital allocation, successful integration of acquisitions, and navigating competitive pressures in key markets. While short-term projections suggest a potential price decline, long-term forecasts anticipate significant appreciation driven by robust fundamentals and margin expansion.

$9.62

CCEL Valuation Report 2026-07-16

Cryo-Cell International operates within cord blood and tissue preservation, a niche of regenerative medicine. Revenue stems from long-term storage fees and services for research entities, though recent performance shows a 2% revenue decrease year-over-year. Profitability relies on high retention rates and efficient cryogenic infrastructure management. The company faces increasing competition, requiring sustained marketing investment, and clinical efficacy of cord blood treatments remains uncertain. Strategic shifts include expansion into cellular therapies via acquisitions and new facilities, demanding significant capital allocation. Financial performance is marked by cyclical volatility, with fluctuating net margins and cash flow, despite consistent gross profitability. While debt is managed proactively, the company’s reliance on debt and potential for dilution necessitate careful monitoring. Valuation relies on metrics beyond traditional ratios, focusing on revenue per unit, customer acquisition cost, and free cash flow. Macroeconomic factors, including GDP, unemployment, and inflation, influence consumer spending on non-essential services like cord blood banking, creating headwinds. Management demonstrates adaptability, shifting strategies in response to challenges, but consistent execution remains key to long-term value creation.

$415.93

ELV Valuation Report 2026-07-16

Elevance Health Inc. demonstrates resilience through strategic cost management and revenue diversification via its Carelon services segment, despite macroeconomic headwinds. Recent earnings exceeded expectations due to favorable medical cost control and disciplined expense management, prompting upward revisions to full-year earnings guidance. Investor focus remains on medical cost trends, with share price appreciation reflecting confidence in the company’s mitigation efforts. Capital allocation prioritizes Carelon and emerging technologies, aiming for long-term growth and enhanced shareholder value. While valuation remains premium, it’s supported by consistent revenue, strong cash flow, and capital return programs. Stable working capital and a defensive profile position the company well in the current environment. Strategic shifts over the past four quarters emphasize operational transformation, with acquisitions and technological integration driving long-term value. Risks include regulatory scrutiny, supply chain vulnerabilities, and competitive pressures, but proactive management and a balanced capital strategy suggest continued solid returns. The company’s focus on value-based care and expanding service offerings is expected to drive margin expansion and sustainable earnings power.

$306.42

JNJ Valuation Report 2026-07-16

Johnson & Johnson (JNJ) is a diversified healthcare company with revenue driven by Innovative Medicine and MedTech segments, consistently generating substantial free cash flow. Recent performance shows continued revenue growth, partially offset by biosimilar competition impacting products like Stelara, though key franchises like Darzalex and Tremfya are mitigating this. Strategic initiatives include integrating AI/robotics into MedTech and a focus on acquisitions (Intra-Cellular Therapies, Shockwave) alongside operational restructuring. While facing headwinds from inflation and potential regulatory changes, JNJ maintains a strong financial position and is actively reshaping its portfolio, including the separation of its Orthopaedics business. Recent balance sheet adjustments reflect funding for acquisitions and consistent shareholder returns through dividends and buybacks. Despite a robust pipeline and defensible market position, investor sentiment demands more pronounced outperformance, and the company’s risk profile has evolved with increasing legal and supply chain challenges. JNJ’s strategic focus on high-growth areas and efficient operations positions it for continued, though potentially cyclical, growth, with a long-term revenue target of $100 billion. Valuation analysis suggests a cautiously optimistic outlook, with a projected price range increasing from approximately $243 in the near term to over $306 long-term, contingent on successful execution and navigating evolving market dynamics.